Developing an mRNA Therapy for DMD with Elixirgen Therapeutics' Aki Ko

We love to hear from our listeners. Send us a message.

Elixirgen Therapeutics' Aki Ko joins Erin Harris to detail the company's Bobcat mRNA therapeutic and how it differs from traditional exon-skipping drugs and AAV-microdystrophin in treating DMD. Regarding delivery, Ko explains the advantage of the mRNA approach over the AAV approach.

Subscribe to the podcast!
Apple | Spotify | YouTube